BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Vancouver - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Vancouver
X-ORIGINAL-URL:https://scienceinvancouver.com
X-WR-CALDESC:Events for Science in Vancouver
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T100000
DTSTAMP:20260407T122826
CREATED:20210908T215410Z
LAST-MODIFIED:20210913T173506Z
UID:18179-1632128400-1632132000@scienceinvancouver.com
SUMMARY:adMare's Global Leaders Series: Dr. George Church
DESCRIPTION:Join us on Monday\, September 20 for adMare’s Global Leaders webinar series\, featuring Dr. George Church from Harvard University. Dr. Church is a legend in the startup biotech space\, having launched 16 spinout companies in 2018 alone.
URL:https://scienceinvancouver.com/event/admares-global-leaders-series-dr-george-church/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/Dr-George-Church.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T100000
DTSTAMP:20260407T122826
CREATED:20210908T215410Z
LAST-MODIFIED:20210908T215410Z
UID:26430-1632128400-1632132000@scienceinvancouver.com
SUMMARY:adMare's Global Leaders Series: Dr. George Church
DESCRIPTION:Join us on Monday\, September 20 for adMare’s Global Leaders webinar series\, featuring Dr. George Church from Harvard University. Dr. Church is a legend in the startup biotech space\, having launched 16 spinout companies in 2018 alone.
URL:https://scienceinvancouver.com/event/admares-global-leaders-series-dr-george-church-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/Dr-George-Church.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T100000
DTSTAMP:20260407T122826
CREATED:20210908T215410Z
LAST-MODIFIED:20210908T215410Z
UID:28045-1632128400-1632132000@scienceinvancouver.com
SUMMARY:adMare's Global Leaders Series: Dr. George Church
DESCRIPTION:Join us on Monday\, September 20 for adMare’s Global Leaders webinar series\, featuring Dr. George Church from Harvard University. Dr. Church is a legend in the startup biotech space\, having launched 16 spinout companies in 2018 alone.
URL:https://scienceinvancouver.com/event/admares-global-leaders-series-dr-george-church-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/Dr-George-Church.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T100000
DTSTAMP:20260407T122826
CREATED:20210908T215410Z
LAST-MODIFIED:20210908T215410Z
UID:31128-1632128400-1632132000@scienceinvancouver.com
SUMMARY:adMare's Global Leaders Series: Dr. George Church
DESCRIPTION:Join us on Monday\, September 20 for adMare’s Global Leaders webinar series\, featuring Dr. George Church from Harvard University. Dr. Church is a legend in the startup biotech space\, having launched 16 spinout companies in 2018 alone.
URL:https://scienceinvancouver.com/event/admares-global-leaders-series-dr-george-church-4/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/Dr-George-Church.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T100000
DTSTAMP:20260407T122826
CREATED:20210908T215410Z
LAST-MODIFIED:20210908T215410Z
UID:32588-1632128400-1632132000@scienceinvancouver.com
SUMMARY:adMare's Global Leaders Series: Dr. George Church
DESCRIPTION:Join us on Monday\, September 20 for adMare’s Global Leaders webinar series\, featuring Dr. George Church from Harvard University. Dr. Church is a legend in the startup biotech space\, having launched 16 spinout companies in 2018 alone.
URL:https://scienceinvancouver.com/event/admares-global-leaders-series-dr-george-church-5/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/Dr-George-Church.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T103000
DTSTAMP:20260407T122826
CREATED:20210916T144447Z
LAST-MODIFIED:20210916T144447Z
UID:18350-1632128400-1632133800@scienceinvancouver.com
SUMMARY:TFRI Pan-Can Seminar Series: BC Cancer Centre for Lymphoid Cancer
DESCRIPTION:This inaugural series\, held every other month\, features TFRI-funded program and project leaders and trainees. \n9:00-9:02am: Welcome by Jim Woodgett\, TFRI President and Scientific Director \n9:02-9:04am: Welcome and Introduction by Marco Marra\, BC Node Leader and Director\, Canada’s Michael Smith Genome Sciences Centre \n9:05 -9:45am: Christian Steidl\, MD\, Research Director\, Centre for Lymphoid Cancer\, BC Cancer\, who will speak on: Introduction to BC Cancer’s Centre for Lymphoid Cancer and The tumour microenvironment of Hodgkin lymphoma at single cell resolution \nTalk overview: In Hodgkin lymphoma (HL)\, the malignant cells are outnumbered by a dominant tumour microenvironment composed of mostly infiltrating immune cells. Modern targeted and immunotherapeutic approaches\, including checkpoint inhibitors\, have proven highly effective; however\, mechanisms of action and treatment failure remain mostly unknown. Characterization of the TME using multiparametric single cell technologies\, such as multicolor immunohistochemistry\, flow-based mass cytometry\, imaging mass cytometry\, and single cell RNAseq have provided unprecedented insight into HL biology\, fueling hope for accelerated development of immunotherapies targeting the tumour microenvironment and predictive biomarker development. \n9:45-10:05am: Brett Collinge\, Graduate Student\, Department of Pathology and Laboratory Medicine\, University of British Columbia\, Scott lab\, Centre for Lymphoid Cancer\, who will speak on: New molecular taxonomies in aggressive B cell lymphomas \nTalk overview: While standard treatment with chemoimmunotherapy cures ~60% of aggressive B-cell lymphomas\, patients with tumours that progress or relapse after frontline therapy have dismal outcomes\, making the development of new treatment strategies a major priority. Recent advances in molecular testing have allowed us to recognize that lymphoma entities can be further refined by introduction of molecular taxonomies grouping patients with similar molecular features and responses to treatment. Integrating molecular diagnostics into the clinic offers a promising avenue for improving outcomes in aggressive B-cell lymphomas. \n10:05-10:25am: Christopher Rushton\, Graduate Student\, Molecular Biology and Biochemistry\, Simon Fraser University\, Morin lab\, who will speak on: Genomic analysis of relapsed-refractory diffuse large B cell lymphoma \nTalk overview: Despite a plethora of treatment options\, patients with relapsed-refractory DLBCL generally have poor outcomes\, and the biology of relapsed disease is poorly understood. We have collected and sequenced samples from patients with relapsed DLBCL to identify somatic mutations that are enriched at the time point of relapse. Comparison to matched pre-treatment tumours revealed evidence of constrained tumour evolution\, diverging biology of early and late relapses\, and mechanisms of treatment resistance. \n10:25-10:30am: Final questions and conclusion
URL:https://scienceinvancouver.com/event/tfri-pan-can-seminar-series-bc-cancer-centre-for-lymphoid-cancer/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/christain-steidl-terry-fox.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T103000
DTSTAMP:20260407T122826
CREATED:20210916T144447Z
LAST-MODIFIED:20210916T144447Z
UID:26436-1632128400-1632133800@scienceinvancouver.com
SUMMARY:TFRI Pan-Can Seminar Series: BC Cancer Centre for Lymphoid Cancer
DESCRIPTION:This inaugural series\, held every other month\, features TFRI-funded program and project leaders and trainees. \n9:00-9:02am: Welcome by Jim Woodgett\, TFRI President and Scientific Director \n9:02-9:04am: Welcome and Introduction by Marco Marra\, BC Node Leader and Director\, Canada’s Michael Smith Genome Sciences Centre \n9:05 -9:45am: Christian Steidl\, MD\, Research Director\, Centre for Lymphoid Cancer\, BC Cancer\, who will speak on: Introduction to BC Cancer’s Centre for Lymphoid Cancer and The tumour microenvironment of Hodgkin lymphoma at single cell resolution \nTalk overview: In Hodgkin lymphoma (HL)\, the malignant cells are outnumbered by a dominant tumour microenvironment composed of mostly infiltrating immune cells. Modern targeted and immunotherapeutic approaches\, including checkpoint inhibitors\, have proven highly effective; however\, mechanisms of action and treatment failure remain mostly unknown. Characterization of the TME using multiparametric single cell technologies\, such as multicolor immunohistochemistry\, flow-based mass cytometry\, imaging mass cytometry\, and single cell RNAseq have provided unprecedented insight into HL biology\, fueling hope for accelerated development of immunotherapies targeting the tumour microenvironment and predictive biomarker development. \n9:45-10:05am: Brett Collinge\, Graduate Student\, Department of Pathology and Laboratory Medicine\, University of British Columbia\, Scott lab\, Centre for Lymphoid Cancer\, who will speak on: New molecular taxonomies in aggressive B cell lymphomas \nTalk overview: While standard treatment with chemoimmunotherapy cures ~60% of aggressive B-cell lymphomas\, patients with tumours that progress or relapse after frontline therapy have dismal outcomes\, making the development of new treatment strategies a major priority. Recent advances in molecular testing have allowed us to recognize that lymphoma entities can be further refined by introduction of molecular taxonomies grouping patients with similar molecular features and responses to treatment. Integrating molecular diagnostics into the clinic offers a promising avenue for improving outcomes in aggressive B-cell lymphomas. \n10:05-10:25am: Christopher Rushton\, Graduate Student\, Molecular Biology and Biochemistry\, Simon Fraser University\, Morin lab\, who will speak on: Genomic analysis of relapsed-refractory diffuse large B cell lymphoma \nTalk overview: Despite a plethora of treatment options\, patients with relapsed-refractory DLBCL generally have poor outcomes\, and the biology of relapsed disease is poorly understood. We have collected and sequenced samples from patients with relapsed DLBCL to identify somatic mutations that are enriched at the time point of relapse. Comparison to matched pre-treatment tumours revealed evidence of constrained tumour evolution\, diverging biology of early and late relapses\, and mechanisms of treatment resistance. \n10:25-10:30am: Final questions and conclusion
URL:https://scienceinvancouver.com/event/tfri-pan-can-seminar-series-bc-cancer-centre-for-lymphoid-cancer-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/christain-steidl-terry-fox.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T103000
DTSTAMP:20260407T122826
CREATED:20210916T144447Z
LAST-MODIFIED:20210916T144447Z
UID:28051-1632128400-1632133800@scienceinvancouver.com
SUMMARY:TFRI Pan-Can Seminar Series: BC Cancer Centre for Lymphoid Cancer
DESCRIPTION:This inaugural series\, held every other month\, features TFRI-funded program and project leaders and trainees. \n9:00-9:02am: Welcome by Jim Woodgett\, TFRI President and Scientific Director \n9:02-9:04am: Welcome and Introduction by Marco Marra\, BC Node Leader and Director\, Canada’s Michael Smith Genome Sciences Centre \n9:05 -9:45am: Christian Steidl\, MD\, Research Director\, Centre for Lymphoid Cancer\, BC Cancer\, who will speak on: Introduction to BC Cancer’s Centre for Lymphoid Cancer and The tumour microenvironment of Hodgkin lymphoma at single cell resolution \nTalk overview: In Hodgkin lymphoma (HL)\, the malignant cells are outnumbered by a dominant tumour microenvironment composed of mostly infiltrating immune cells. Modern targeted and immunotherapeutic approaches\, including checkpoint inhibitors\, have proven highly effective; however\, mechanisms of action and treatment failure remain mostly unknown. Characterization of the TME using multiparametric single cell technologies\, such as multicolor immunohistochemistry\, flow-based mass cytometry\, imaging mass cytometry\, and single cell RNAseq have provided unprecedented insight into HL biology\, fueling hope for accelerated development of immunotherapies targeting the tumour microenvironment and predictive biomarker development. \n9:45-10:05am: Brett Collinge\, Graduate Student\, Department of Pathology and Laboratory Medicine\, University of British Columbia\, Scott lab\, Centre for Lymphoid Cancer\, who will speak on: New molecular taxonomies in aggressive B cell lymphomas \nTalk overview: While standard treatment with chemoimmunotherapy cures ~60% of aggressive B-cell lymphomas\, patients with tumours that progress or relapse after frontline therapy have dismal outcomes\, making the development of new treatment strategies a major priority. Recent advances in molecular testing have allowed us to recognize that lymphoma entities can be further refined by introduction of molecular taxonomies grouping patients with similar molecular features and responses to treatment. Integrating molecular diagnostics into the clinic offers a promising avenue for improving outcomes in aggressive B-cell lymphomas. \n10:05-10:25am: Christopher Rushton\, Graduate Student\, Molecular Biology and Biochemistry\, Simon Fraser University\, Morin lab\, who will speak on: Genomic analysis of relapsed-refractory diffuse large B cell lymphoma \nTalk overview: Despite a plethora of treatment options\, patients with relapsed-refractory DLBCL generally have poor outcomes\, and the biology of relapsed disease is poorly understood. We have collected and sequenced samples from patients with relapsed DLBCL to identify somatic mutations that are enriched at the time point of relapse. Comparison to matched pre-treatment tumours revealed evidence of constrained tumour evolution\, diverging biology of early and late relapses\, and mechanisms of treatment resistance. \n10:25-10:30am: Final questions and conclusion
URL:https://scienceinvancouver.com/event/tfri-pan-can-seminar-series-bc-cancer-centre-for-lymphoid-cancer-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/christain-steidl-terry-fox.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T103000
DTSTAMP:20260407T122826
CREATED:20210916T144447Z
LAST-MODIFIED:20210916T144447Z
UID:31134-1632128400-1632133800@scienceinvancouver.com
SUMMARY:TFRI Pan-Can Seminar Series: BC Cancer Centre for Lymphoid Cancer
DESCRIPTION:This inaugural series\, held every other month\, features TFRI-funded program and project leaders and trainees. \n9:00-9:02am: Welcome by Jim Woodgett\, TFRI President and Scientific Director \n9:02-9:04am: Welcome and Introduction by Marco Marra\, BC Node Leader and Director\, Canada’s Michael Smith Genome Sciences Centre \n9:05 -9:45am: Christian Steidl\, MD\, Research Director\, Centre for Lymphoid Cancer\, BC Cancer\, who will speak on: Introduction to BC Cancer’s Centre for Lymphoid Cancer and The tumour microenvironment of Hodgkin lymphoma at single cell resolution \nTalk overview: In Hodgkin lymphoma (HL)\, the malignant cells are outnumbered by a dominant tumour microenvironment composed of mostly infiltrating immune cells. Modern targeted and immunotherapeutic approaches\, including checkpoint inhibitors\, have proven highly effective; however\, mechanisms of action and treatment failure remain mostly unknown. Characterization of the TME using multiparametric single cell technologies\, such as multicolor immunohistochemistry\, flow-based mass cytometry\, imaging mass cytometry\, and single cell RNAseq have provided unprecedented insight into HL biology\, fueling hope for accelerated development of immunotherapies targeting the tumour microenvironment and predictive biomarker development. \n9:45-10:05am: Brett Collinge\, Graduate Student\, Department of Pathology and Laboratory Medicine\, University of British Columbia\, Scott lab\, Centre for Lymphoid Cancer\, who will speak on: New molecular taxonomies in aggressive B cell lymphomas \nTalk overview: While standard treatment with chemoimmunotherapy cures ~60% of aggressive B-cell lymphomas\, patients with tumours that progress or relapse after frontline therapy have dismal outcomes\, making the development of new treatment strategies a major priority. Recent advances in molecular testing have allowed us to recognize that lymphoma entities can be further refined by introduction of molecular taxonomies grouping patients with similar molecular features and responses to treatment. Integrating molecular diagnostics into the clinic offers a promising avenue for improving outcomes in aggressive B-cell lymphomas. \n10:05-10:25am: Christopher Rushton\, Graduate Student\, Molecular Biology and Biochemistry\, Simon Fraser University\, Morin lab\, who will speak on: Genomic analysis of relapsed-refractory diffuse large B cell lymphoma \nTalk overview: Despite a plethora of treatment options\, patients with relapsed-refractory DLBCL generally have poor outcomes\, and the biology of relapsed disease is poorly understood. We have collected and sequenced samples from patients with relapsed DLBCL to identify somatic mutations that are enriched at the time point of relapse. Comparison to matched pre-treatment tumours revealed evidence of constrained tumour evolution\, diverging biology of early and late relapses\, and mechanisms of treatment resistance. \n10:25-10:30am: Final questions and conclusion
URL:https://scienceinvancouver.com/event/tfri-pan-can-seminar-series-bc-cancer-centre-for-lymphoid-cancer-4/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/christain-steidl-terry-fox.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210920T090000
DTEND;TZID=America/Vancouver:20210920T103000
DTSTAMP:20260407T122826
CREATED:20210916T144447Z
LAST-MODIFIED:20210916T144447Z
UID:32594-1632128400-1632133800@scienceinvancouver.com
SUMMARY:TFRI Pan-Can Seminar Series: BC Cancer Centre for Lymphoid Cancer
DESCRIPTION:This inaugural series\, held every other month\, features TFRI-funded program and project leaders and trainees. \n9:00-9:02am: Welcome by Jim Woodgett\, TFRI President and Scientific Director \n9:02-9:04am: Welcome and Introduction by Marco Marra\, BC Node Leader and Director\, Canada’s Michael Smith Genome Sciences Centre \n9:05 -9:45am: Christian Steidl\, MD\, Research Director\, Centre for Lymphoid Cancer\, BC Cancer\, who will speak on: Introduction to BC Cancer’s Centre for Lymphoid Cancer and The tumour microenvironment of Hodgkin lymphoma at single cell resolution \nTalk overview: In Hodgkin lymphoma (HL)\, the malignant cells are outnumbered by a dominant tumour microenvironment composed of mostly infiltrating immune cells. Modern targeted and immunotherapeutic approaches\, including checkpoint inhibitors\, have proven highly effective; however\, mechanisms of action and treatment failure remain mostly unknown. Characterization of the TME using multiparametric single cell technologies\, such as multicolor immunohistochemistry\, flow-based mass cytometry\, imaging mass cytometry\, and single cell RNAseq have provided unprecedented insight into HL biology\, fueling hope for accelerated development of immunotherapies targeting the tumour microenvironment and predictive biomarker development. \n9:45-10:05am: Brett Collinge\, Graduate Student\, Department of Pathology and Laboratory Medicine\, University of British Columbia\, Scott lab\, Centre for Lymphoid Cancer\, who will speak on: New molecular taxonomies in aggressive B cell lymphomas \nTalk overview: While standard treatment with chemoimmunotherapy cures ~60% of aggressive B-cell lymphomas\, patients with tumours that progress or relapse after frontline therapy have dismal outcomes\, making the development of new treatment strategies a major priority. Recent advances in molecular testing have allowed us to recognize that lymphoma entities can be further refined by introduction of molecular taxonomies grouping patients with similar molecular features and responses to treatment. Integrating molecular diagnostics into the clinic offers a promising avenue for improving outcomes in aggressive B-cell lymphomas. \n10:05-10:25am: Christopher Rushton\, Graduate Student\, Molecular Biology and Biochemistry\, Simon Fraser University\, Morin lab\, who will speak on: Genomic analysis of relapsed-refractory diffuse large B cell lymphoma \nTalk overview: Despite a plethora of treatment options\, patients with relapsed-refractory DLBCL generally have poor outcomes\, and the biology of relapsed disease is poorly understood. We have collected and sequenced samples from patients with relapsed DLBCL to identify somatic mutations that are enriched at the time point of relapse. Comparison to matched pre-treatment tumours revealed evidence of constrained tumour evolution\, diverging biology of early and late relapses\, and mechanisms of treatment resistance. \n10:25-10:30am: Final questions and conclusion
URL:https://scienceinvancouver.com/event/tfri-pan-can-seminar-series-bc-cancer-centre-for-lymphoid-cancer-5/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/09/christain-steidl-terry-fox.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T110000
DTSTAMP:20260407T122826
CREATED:20210908T224214Z
LAST-MODIFIED:20210908T224442Z
UID:18210-1632218400-1632222000@scienceinvancouver.com
SUMMARY:Lipid and RNA Nanomedicines to Control Bleeding and Thrombosis
DESCRIPTION:Dr. Christian Kastrup \nAssociate Professor in the Michael Smith Laboratories and Department of Biochemistry & Molecular Biology at the University of British Columbia; member of the Centre for Blood Research and the School of Biomedical Engineering \nTuesday 21 September 2021 \n10:00 – 11:00 am PDT | 1:00 – 2:00 pm EDT \nThis lecture will be delivered online using Zoom \nBlood coagulation is necessary to stop bleeds\, but an imbalance of the enzymes that form\, inhibit and degrade blood clots can lead to bleeding disorders\, failure to stop severe hemorrhage after injury\, or formation of thromboses. Gene therapy\, using RNA and lipid nanoparticles\, can be used to modulate the concentration of these enzymes and correct any imbalance. This talk will highlight the applicability of RNA and lipid nanoparticles to control the expression of endogenous and exogenous proteins in the liver and in platelets\, for the goal of creating useful therapies for trauma\, rare bleeding disorders\, and thrombosis. \nDr. Christian Kastrup did his postdoctoral fellowship in at MIT\, where he specialized in engineering biomaterials for cardiovascular drug delivery. He received his PhD at the University of Chicago\, where he specialized in chemical biology\, microfluidics\, and blood coagulation. His lab at UBC utilizes biochemical engineering to solve problems related to hemostasis and hemorrhage. They investigate\, utilize\, and mimic the biochemistry and biophysical dynamics of blood coagulation to create innovative materials that perform new functions inside of blood vessels\, and work to develop treatments for severe hemorrhage. \nDr. Kastrup has received many accolades\, the most recent one being the Sir Major Banting Award from the True Patriot Love Foundation. He is the Chief Scientific Officer of CoMotion Drug Delivery Systems\, Inc.\, which is working to develop hemostatic agents for severe combat and surgical hemorrhage.
URL:https://scienceinvancouver.com/event/lipid-and-rna-nanomedicines-to-control-bleeding-and-thrombosis/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T110000
DTSTAMP:20260407T122826
CREATED:20210908T224214Z
LAST-MODIFIED:20210908T224214Z
UID:26431-1632218400-1632222000@scienceinvancouver.com
SUMMARY:Lipid and RNA Nanomedicines to Control Bleeding and Thrombosis
DESCRIPTION:Dr. Christian Kastrup \nAssociate Professor in the Michael Smith Laboratories and Department of Biochemistry & Molecular Biology at the University of British Columbia; member of the Centre for Blood Research and the School of Biomedical Engineering \nTuesday 21 September 2021 \n10:00 – 11:00 am PDT | 1:00 – 2:00 pm EDT \nThis lecture will be delivered online using Zoom \nBlood coagulation is necessary to stop bleeds\, but an imbalance of the enzymes that form\, inhibit and degrade blood clots can lead to bleeding disorders\, failure to stop severe hemorrhage after injury\, or formation of thromboses. Gene therapy\, using RNA and lipid nanoparticles\, can be used to modulate the concentration of these enzymes and correct any imbalance. This talk will highlight the applicability of RNA and lipid nanoparticles to control the expression of endogenous and exogenous proteins in the liver and in platelets\, for the goal of creating useful therapies for trauma\, rare bleeding disorders\, and thrombosis. \nDr. Christian Kastrup did his postdoctoral fellowship in at MIT\, where he specialized in engineering biomaterials for cardiovascular drug delivery. He received his PhD at the University of Chicago\, where he specialized in chemical biology\, microfluidics\, and blood coagulation. His lab at UBC utilizes biochemical engineering to solve problems related to hemostasis and hemorrhage. They investigate\, utilize\, and mimic the biochemistry and biophysical dynamics of blood coagulation to create innovative materials that perform new functions inside of blood vessels\, and work to develop treatments for severe hemorrhage. \nDr. Kastrup has received many accolades\, the most recent one being the Sir Major Banting Award from the True Patriot Love Foundation. He is the Chief Scientific Officer of CoMotion Drug Delivery Systems\, Inc.\, which is working to develop hemostatic agents for severe combat and surgical hemorrhage.
URL:https://scienceinvancouver.com/event/lipid-and-rna-nanomedicines-to-control-bleeding-and-thrombosis-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T110000
DTSTAMP:20260407T122826
CREATED:20210908T224214Z
LAST-MODIFIED:20210908T224214Z
UID:28046-1632218400-1632222000@scienceinvancouver.com
SUMMARY:Lipid and RNA Nanomedicines to Control Bleeding and Thrombosis
DESCRIPTION:Dr. Christian Kastrup \nAssociate Professor in the Michael Smith Laboratories and Department of Biochemistry & Molecular Biology at the University of British Columbia; member of the Centre for Blood Research and the School of Biomedical Engineering \nTuesday 21 September 2021 \n10:00 – 11:00 am PDT | 1:00 – 2:00 pm EDT \nThis lecture will be delivered online using Zoom \nBlood coagulation is necessary to stop bleeds\, but an imbalance of the enzymes that form\, inhibit and degrade blood clots can lead to bleeding disorders\, failure to stop severe hemorrhage after injury\, or formation of thromboses. Gene therapy\, using RNA and lipid nanoparticles\, can be used to modulate the concentration of these enzymes and correct any imbalance. This talk will highlight the applicability of RNA and lipid nanoparticles to control the expression of endogenous and exogenous proteins in the liver and in platelets\, for the goal of creating useful therapies for trauma\, rare bleeding disorders\, and thrombosis. \nDr. Christian Kastrup did his postdoctoral fellowship in at MIT\, where he specialized in engineering biomaterials for cardiovascular drug delivery. He received his PhD at the University of Chicago\, where he specialized in chemical biology\, microfluidics\, and blood coagulation. His lab at UBC utilizes biochemical engineering to solve problems related to hemostasis and hemorrhage. They investigate\, utilize\, and mimic the biochemistry and biophysical dynamics of blood coagulation to create innovative materials that perform new functions inside of blood vessels\, and work to develop treatments for severe hemorrhage. \nDr. Kastrup has received many accolades\, the most recent one being the Sir Major Banting Award from the True Patriot Love Foundation. He is the Chief Scientific Officer of CoMotion Drug Delivery Systems\, Inc.\, which is working to develop hemostatic agents for severe combat and surgical hemorrhage.
URL:https://scienceinvancouver.com/event/lipid-and-rna-nanomedicines-to-control-bleeding-and-thrombosis-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T110000
DTSTAMP:20260407T122826
CREATED:20210908T224214Z
LAST-MODIFIED:20210908T224214Z
UID:31129-1632218400-1632222000@scienceinvancouver.com
SUMMARY:Lipid and RNA Nanomedicines to Control Bleeding and Thrombosis
DESCRIPTION:Dr. Christian Kastrup \nAssociate Professor in the Michael Smith Laboratories and Department of Biochemistry & Molecular Biology at the University of British Columbia; member of the Centre for Blood Research and the School of Biomedical Engineering \nTuesday 21 September 2021 \n10:00 – 11:00 am PDT | 1:00 – 2:00 pm EDT \nThis lecture will be delivered online using Zoom \nBlood coagulation is necessary to stop bleeds\, but an imbalance of the enzymes that form\, inhibit and degrade blood clots can lead to bleeding disorders\, failure to stop severe hemorrhage after injury\, or formation of thromboses. Gene therapy\, using RNA and lipid nanoparticles\, can be used to modulate the concentration of these enzymes and correct any imbalance. This talk will highlight the applicability of RNA and lipid nanoparticles to control the expression of endogenous and exogenous proteins in the liver and in platelets\, for the goal of creating useful therapies for trauma\, rare bleeding disorders\, and thrombosis. \nDr. Christian Kastrup did his postdoctoral fellowship in at MIT\, where he specialized in engineering biomaterials for cardiovascular drug delivery. He received his PhD at the University of Chicago\, where he specialized in chemical biology\, microfluidics\, and blood coagulation. His lab at UBC utilizes biochemical engineering to solve problems related to hemostasis and hemorrhage. They investigate\, utilize\, and mimic the biochemistry and biophysical dynamics of blood coagulation to create innovative materials that perform new functions inside of blood vessels\, and work to develop treatments for severe hemorrhage. \nDr. Kastrup has received many accolades\, the most recent one being the Sir Major Banting Award from the True Patriot Love Foundation. He is the Chief Scientific Officer of CoMotion Drug Delivery Systems\, Inc.\, which is working to develop hemostatic agents for severe combat and surgical hemorrhage.
URL:https://scienceinvancouver.com/event/lipid-and-rna-nanomedicines-to-control-bleeding-and-thrombosis-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T110000
DTSTAMP:20260407T122826
CREATED:20210908T224214Z
LAST-MODIFIED:20210908T224214Z
UID:32589-1632218400-1632222000@scienceinvancouver.com
SUMMARY:Lipid and RNA Nanomedicines to Control Bleeding and Thrombosis
DESCRIPTION:Dr. Christian Kastrup \nAssociate Professor in the Michael Smith Laboratories and Department of Biochemistry & Molecular Biology at the University of British Columbia; member of the Centre for Blood Research and the School of Biomedical Engineering \nTuesday 21 September 2021 \n10:00 – 11:00 am PDT | 1:00 – 2:00 pm EDT \nThis lecture will be delivered online using Zoom \nBlood coagulation is necessary to stop bleeds\, but an imbalance of the enzymes that form\, inhibit and degrade blood clots can lead to bleeding disorders\, failure to stop severe hemorrhage after injury\, or formation of thromboses. Gene therapy\, using RNA and lipid nanoparticles\, can be used to modulate the concentration of these enzymes and correct any imbalance. This talk will highlight the applicability of RNA and lipid nanoparticles to control the expression of endogenous and exogenous proteins in the liver and in platelets\, for the goal of creating useful therapies for trauma\, rare bleeding disorders\, and thrombosis. \nDr. Christian Kastrup did his postdoctoral fellowship in at MIT\, where he specialized in engineering biomaterials for cardiovascular drug delivery. He received his PhD at the University of Chicago\, where he specialized in chemical biology\, microfluidics\, and blood coagulation. His lab at UBC utilizes biochemical engineering to solve problems related to hemostasis and hemorrhage. They investigate\, utilize\, and mimic the biochemistry and biophysical dynamics of blood coagulation to create innovative materials that perform new functions inside of blood vessels\, and work to develop treatments for severe hemorrhage. \nDr. Kastrup has received many accolades\, the most recent one being the Sir Major Banting Award from the True Patriot Love Foundation. He is the Chief Scientific Officer of CoMotion Drug Delivery Systems\, Inc.\, which is working to develop hemostatic agents for severe combat and surgical hemorrhage.
URL:https://scienceinvancouver.com/event/lipid-and-rna-nanomedicines-to-control-bleeding-and-thrombosis-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T160000
DTSTAMP:20260407T122826
CREATED:20210716T221747Z
LAST-MODIFIED:20210823T212314Z
UID:17426-1632218400-1632240000@scienceinvancouver.com
SUMMARY:BC Cancer Research Day
DESCRIPTION:TUESDAY\, SEPTEMBER 21ST\, 2021 | 10 AM – 4 PM | ZOOM\n\n\n\n\n\n\n\nRegistration Deadline: September 15\, 2021 | Abstract Deadline: August 1\, 2021 \nQUICK LINKS\n\n\nKeynote Speakers \n\n\nDay Schedule \n\n\nDeadlines
URL:https://scienceinvancouver.com/event/bc-cancer-research-day-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/BCCancerResearchDay2021.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T160000
DTSTAMP:20260407T122826
CREATED:20210716T221747Z
LAST-MODIFIED:20210716T221747Z
UID:26414-1632218400-1632240000@scienceinvancouver.com
SUMMARY:BC Cancer Research Day
DESCRIPTION:TUESDAY\, SEPTEMBER 21ST\, 2021 | 10 AM – 4 PM | ZOOM\n\n\n\n\n\n\n\nRegistration Deadline: September 15\, 2021 | Abstract Deadline: August 1\, 2021 \nQUICK LINKS\n\n\nKeynote Speakers \n\n\nDay Schedule \n\n\nDeadlines
URL:https://scienceinvancouver.com/event/bc-cancer-research-day-2-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/BCCancerResearchDay2021.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T160000
DTSTAMP:20260407T122826
CREATED:20210716T221747Z
LAST-MODIFIED:20210716T221747Z
UID:28029-1632218400-1632240000@scienceinvancouver.com
SUMMARY:BC Cancer Research Day
DESCRIPTION:TUESDAY\, SEPTEMBER 21ST\, 2021 | 10 AM – 4 PM | ZOOM\n\n\n\n\n\n\n\nRegistration Deadline: September 15\, 2021 | Abstract Deadline: August 1\, 2021 \nQUICK LINKS\n\n\nKeynote Speakers \n\n\nDay Schedule \n\n\nDeadlines
URL:https://scienceinvancouver.com/event/bc-cancer-research-day-2-3/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/BCCancerResearchDay2021.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T160000
DTSTAMP:20260407T122826
CREATED:20210716T221747Z
LAST-MODIFIED:20210716T221747Z
UID:31112-1632218400-1632240000@scienceinvancouver.com
SUMMARY:BC Cancer Research Day
DESCRIPTION:TUESDAY\, SEPTEMBER 21ST\, 2021 | 10 AM – 4 PM | ZOOM\n\n\n\n\n\n\n\nRegistration Deadline: September 15\, 2021 | Abstract Deadline: August 1\, 2021 \nQUICK LINKS\n\n\nKeynote Speakers \n\n\nDay Schedule \n\n\nDeadlines
URL:https://scienceinvancouver.com/event/bc-cancer-research-day-2-4/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/BCCancerResearchDay2021.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210921T100000
DTEND;TZID=America/Vancouver:20210921T160000
DTSTAMP:20260407T122826
CREATED:20210716T221747Z
LAST-MODIFIED:20210716T221747Z
UID:32572-1632218400-1632240000@scienceinvancouver.com
SUMMARY:BC Cancer Research Day
DESCRIPTION:TUESDAY\, SEPTEMBER 21ST\, 2021 | 10 AM – 4 PM | ZOOM\n\n\n\n\n\n\n\nRegistration Deadline: September 15\, 2021 | Abstract Deadline: August 1\, 2021 \nQUICK LINKS\n\n\nKeynote Speakers \n\n\nDay Schedule \n\n\nDeadlines
URL:https://scienceinvancouver.com/event/bc-cancer-research-day-2-5/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2021/08/BCCancerResearchDay2021.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210922T110000
DTSTAMP:20260407T122826
CREATED:20210908T225440Z
LAST-MODIFIED:20210908T225440Z
UID:18221-1632304800-1632308400@scienceinvancouver.com
SUMMARY:Patient-Oriented Research and Knowledge Translation in Arthritis Rehabilitation
DESCRIPTION:Linda C. Li\, PhD\, M.Sc.\, B.Sc. (PT)\nScientist\, CHÉOS \nProfessor\, Department of Physical Therapy\, Faculty of Medicine\, UBC\nCanada Research Chair in Patient-Oriented Knowledge Translation\nHarold Robinson/Arthritis Society Chair in Arthritic Diseases\, UBC\nSenior Scientist\, Arthritis Research Canada \nBillions of dollars have been invested globally in health research\, but the knowledge is unlikely to translate into health benefits if it is not being used in clinical practice or by individuals to inform their action. The purpose of this presentation is to discuss recent research that aims to modernize arthritis rehabilitation and improve the health of people with arthritis. \nThis presentation consists of two parts. First\, Dr. Li will discuss recent research on digital tools for promoting physical activity in people with arthritis. Second\, she will provide examples of involving patient partners in the development\, evaluation\, and knowledge translation of these tools. A new framework will be introduced to guide the process of meaningful patient engagement in the research process. \nThis talk is open and registration is required. It is part of our Work in Progress Seminar Series.
URL:https://scienceinvancouver.com/event/patient-oriented-research-and-knowledge-translation-in-arthritis-rehabilitation/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210922T110000
DTSTAMP:20260407T122826
CREATED:20210908T225440Z
LAST-MODIFIED:20210908T225440Z
UID:26434-1632304800-1632308400@scienceinvancouver.com
SUMMARY:Patient-Oriented Research and Knowledge Translation in Arthritis Rehabilitation
DESCRIPTION:Linda C. Li\, PhD\, M.Sc.\, B.Sc. (PT)\nScientist\, CHÉOS \nProfessor\, Department of Physical Therapy\, Faculty of Medicine\, UBC\nCanada Research Chair in Patient-Oriented Knowledge Translation\nHarold Robinson/Arthritis Society Chair in Arthritic Diseases\, UBC\nSenior Scientist\, Arthritis Research Canada \nBillions of dollars have been invested globally in health research\, but the knowledge is unlikely to translate into health benefits if it is not being used in clinical practice or by individuals to inform their action. The purpose of this presentation is to discuss recent research that aims to modernize arthritis rehabilitation and improve the health of people with arthritis. \nThis presentation consists of two parts. First\, Dr. Li will discuss recent research on digital tools for promoting physical activity in people with arthritis. Second\, she will provide examples of involving patient partners in the development\, evaluation\, and knowledge translation of these tools. A new framework will be introduced to guide the process of meaningful patient engagement in the research process. \nThis talk is open and registration is required. It is part of our Work in Progress Seminar Series.
URL:https://scienceinvancouver.com/event/patient-oriented-research-and-knowledge-translation-in-arthritis-rehabilitation-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210922T110000
DTSTAMP:20260407T122826
CREATED:20210908T225440Z
LAST-MODIFIED:20210908T225440Z
UID:28049-1632304800-1632308400@scienceinvancouver.com
SUMMARY:Patient-Oriented Research and Knowledge Translation in Arthritis Rehabilitation
DESCRIPTION:Linda C. Li\, PhD\, M.Sc.\, B.Sc. (PT)\nScientist\, CHÉOS \nProfessor\, Department of Physical Therapy\, Faculty of Medicine\, UBC\nCanada Research Chair in Patient-Oriented Knowledge Translation\nHarold Robinson/Arthritis Society Chair in Arthritic Diseases\, UBC\nSenior Scientist\, Arthritis Research Canada \nBillions of dollars have been invested globally in health research\, but the knowledge is unlikely to translate into health benefits if it is not being used in clinical practice or by individuals to inform their action. The purpose of this presentation is to discuss recent research that aims to modernize arthritis rehabilitation and improve the health of people with arthritis. \nThis presentation consists of two parts. First\, Dr. Li will discuss recent research on digital tools for promoting physical activity in people with arthritis. Second\, she will provide examples of involving patient partners in the development\, evaluation\, and knowledge translation of these tools. A new framework will be introduced to guide the process of meaningful patient engagement in the research process. \nThis talk is open and registration is required. It is part of our Work in Progress Seminar Series.
URL:https://scienceinvancouver.com/event/patient-oriented-research-and-knowledge-translation-in-arthritis-rehabilitation-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210922T110000
DTSTAMP:20260407T122826
CREATED:20210908T225440Z
LAST-MODIFIED:20210908T225440Z
UID:31132-1632304800-1632308400@scienceinvancouver.com
SUMMARY:Patient-Oriented Research and Knowledge Translation in Arthritis Rehabilitation
DESCRIPTION:Linda C. Li\, PhD\, M.Sc.\, B.Sc. (PT)\nScientist\, CHÉOS \nProfessor\, Department of Physical Therapy\, Faculty of Medicine\, UBC\nCanada Research Chair in Patient-Oriented Knowledge Translation\nHarold Robinson/Arthritis Society Chair in Arthritic Diseases\, UBC\nSenior Scientist\, Arthritis Research Canada \nBillions of dollars have been invested globally in health research\, but the knowledge is unlikely to translate into health benefits if it is not being used in clinical practice or by individuals to inform their action. The purpose of this presentation is to discuss recent research that aims to modernize arthritis rehabilitation and improve the health of people with arthritis. \nThis presentation consists of two parts. First\, Dr. Li will discuss recent research on digital tools for promoting physical activity in people with arthritis. Second\, she will provide examples of involving patient partners in the development\, evaluation\, and knowledge translation of these tools. A new framework will be introduced to guide the process of meaningful patient engagement in the research process. \nThis talk is open and registration is required. It is part of our Work in Progress Seminar Series.
URL:https://scienceinvancouver.com/event/patient-oriented-research-and-knowledge-translation-in-arthritis-rehabilitation-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210922T110000
DTSTAMP:20260407T122826
CREATED:20210908T225440Z
LAST-MODIFIED:20210908T225440Z
UID:32592-1632304800-1632308400@scienceinvancouver.com
SUMMARY:Patient-Oriented Research and Knowledge Translation in Arthritis Rehabilitation
DESCRIPTION:Linda C. Li\, PhD\, M.Sc.\, B.Sc. (PT)\nScientist\, CHÉOS \nProfessor\, Department of Physical Therapy\, Faculty of Medicine\, UBC\nCanada Research Chair in Patient-Oriented Knowledge Translation\nHarold Robinson/Arthritis Society Chair in Arthritic Diseases\, UBC\nSenior Scientist\, Arthritis Research Canada \nBillions of dollars have been invested globally in health research\, but the knowledge is unlikely to translate into health benefits if it is not being used in clinical practice or by individuals to inform their action. The purpose of this presentation is to discuss recent research that aims to modernize arthritis rehabilitation and improve the health of people with arthritis. \nThis presentation consists of two parts. First\, Dr. Li will discuss recent research on digital tools for promoting physical activity in people with arthritis. Second\, she will provide examples of involving patient partners in the development\, evaluation\, and knowledge translation of these tools. A new framework will be introduced to guide the process of meaningful patient engagement in the research process. \nThis talk is open and registration is required. It is part of our Work in Progress Seminar Series.
URL:https://scienceinvancouver.com/event/patient-oriented-research-and-knowledge-translation-in-arthritis-rehabilitation-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260407T122826
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:18337-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260407T122826
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:26435-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260407T122826
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:28050-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260407T122826
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:31133-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210922T100000
DTEND;TZID=America/Vancouver:20210923T130000
DTSTAMP:20260407T122826
CREATED:20210915T234450Z
LAST-MODIFIED:20210915T234450Z
UID:32593-1632304800-1632402000@scienceinvancouver.com
SUMMARY:UBC Tissue Clearing and Expansion 2021
DESCRIPTION:BCREGMED and the Dynamic Brain Circuits in Health & Disease team are excited to offer a TWO DAY online workshop to facilitate the use of tissue clearing and expansion techniques in the research lab. \nSeptember 22nd and 23rd\n10AM – 1PM both days\nZOOM \nPurpose\nBiological specimens are intrinsically difficult to image.  Currently used tools and methods\, which cut two-dimensional sections of tissue samples to provide insight into the cellular components\, lack in their ability to reveal the systemic nature of tissues and organs which are inherently three-dimensional. On the other hand\, imaging deep into intact tissues brings with it its own problems as a result of the obscuring effects of light scatter and the limitations of most commercial microscopes. \nTechniques to eliminate this scatter and provide understanding into the true behavior of tissues and organs have been developed\, however to our knowledge these techniques being under-utilized in research labs in BC due to their complexity and lack of appropriate equipment. With the recent purchase of a light sheet microscope for the School of Biomedical Engineering and a lattice light sheet microscope expected at the Centre for Brain Health\, tissue clearing and expansion will be made possible however training is needed on the various protocols of expansion and clearing\, 3D image analysis\, and troubleshooting to make sure these techniques are implemented effectively.
URL:https://scienceinvancouver.com/event/ubc-tissue-clearing-and-expansion-2021-5/
LOCATION:Online
END:VEVENT
END:VCALENDAR